BC Week In Review | Oct 22, 2007
Company News

HealthLinx, Proaegis, Monash University gastrointestinal, pulmonary news

Diagnostic company HTX will spin out its CR014 drug development assets into Proaegis. The peptide that has broad-spectrum activity in vascular leak is in preclinical testing to treat acute respiratory distress syndrome (ARDS) and is...
BC Week In Review | Aug 6, 2007
Company News

HealthLinx, University of Virginia deal

HTX (formerly Cryptome Pharmaceuticals Ltd. ) and the university expanded an August 2006 deal to give HTX rights to the university's IP related to CR014 . The original deal gave HTX exclusive, worldwide rights to develop and...
BC Week In Review | Sep 26, 2005
Company News

Cryptome, University of Virginia deal

CRP and the university partnered to discover and validate molecules involved in vascular leak. Also, CRP is in-licensing the university's CR014, a peptide that has broad-spectrum activity in vascular leak. Cryptome Pharmaceuticals Ltd. (ASX:CRP), Melbourne,...
BC Week In Review | Feb 28, 2005
Company News

Cryptome, University of Virginia deal

The university granted CRP a 12-month option to exclusively license U.S. rights to a class of protein-derived compounds that have anti-inflammatory properties. The lead compound, CR014, prevented leakage of plasma into the lung as well...
Items per page:
1 - 4 of 4